SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Diagnocure CUR
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert Dirks who wrote (87)8/22/2000 10:33:25 PM
From: Mr. L. Neufeldt  Read Replies (2) of 132
 
I hope you all bought more below $2.00. I doubt it will be that low again. ImmunoCyt sales should hit around $600K - $700K this year. Revenues for next year should be double these amounts. The tests are good, however, you have to convince the urologists doing the tests. This is taking time but DAKO has their people going around the country. With countries all over the world complaining about medical costs, inexpensive tests like these will become more the norm.

CUR is still years ahead of the competition with their uPM3 test. Buy on weakness...we'll be hearing more from the company when the fourth quarter report comes out in September. There is still only 19 million shares in this company and most are closely held.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News